Fusion Protein Or Fusion Polypeptide (i.e., Expression Product Of Gene Fusion) Patents (Class 424/192.1)
-
Publication number: 20140017272Abstract: Delivery systems and methods are provided for delivering a biologically active protein to a host animal. The systems and methods provided include obtaining an algal cell transformed by an expression vector, the expression vector comprising a nucleotide sequence coding for the biologically active protein, operably linked to a promoter. In one illustrated embodiment, the biologically active protein is an antigenic epitope and upon administration to the animal the algal cell induces an immune response in the host animal.Type: ApplicationFiled: January 2, 2013Publication date: January 16, 2014Applicants: The Ohio State University Research Foundation, ALGAEOMICS LLCInventor: Richard T. Sayre
-
Publication number: 20140017269Abstract: Genes for proteins which spontaneously form dimers and/or oligomers can be recombinantly linked together, which upon expression in E. coli produces stable dimeric fusion proteins that spontaneously self-assemble into enormous, polyvalent complexes having increased immunogenicity and functionality. Linear, network and agglomerate complexes with enormous sizes and polyvalences are constructed using glutathione S-transferase, Norovirus P domains (NoV P? and NoV+), the protruding (P) domain of hepatitis E virus (HEV P), the astrovirus P domain (AstV), a monomeric peptide epitope (M2e of influenza virus), and/or a protein antigen (VP8* of rotavirus) fused in different combinations. The resulting complexes can contain hundreds to thousands NoV P-protein, HEV, AstV, M2e and/or VP8* copies and exhibit higher immunogenicity than the individual proteins alone.Type: ApplicationFiled: March 14, 2013Publication date: January 16, 2014Inventors: Ming TAN, Xi Jiang, Leyi Wang
-
Publication number: 20140017273Abstract: The present disclosure relates to albumin fusion protein including an angiogenesis inhibiting peptide, or a fragment or variant thereof, and albumin, or a fragment or variant thereof. The fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The disclosure includes therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits, as well as nucleic acid molecules encoding the albumin fusion proteins, vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins using these nucleic acids, vectors, and/or host cells. The disclosure further relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor angiogenesis induced cell fusion.Type: ApplicationFiled: July 18, 2013Publication date: January 16, 2014Inventors: Darrell Sleep, ILHAN Celik, Johanna Hay, Oliver Kisker, Peter Mertins, Hans-Peter Hauser
-
Patent number: 8628779Abstract: The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects.Type: GrantFiled: September 8, 2006Date of Patent: January 14, 2014Assignees: Institut Pasteur, Genticel, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche ScientifiqueInventors: Xavier-Edmond-Edouard Preville, Claude Leclerc, Daniel Ladant, Benedikt Timmerman
-
Patent number: 8628775Abstract: Multimeric compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The multimeric compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as inflammatory diseases, autoimmune diseases, transplant rejection, and allergic diseases.Type: GrantFiled: September 18, 2009Date of Patent: January 14, 2014Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang
-
Publication number: 20140010831Abstract: Compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include epitopes of the HER-2 proteins.Type: ApplicationFiled: May 30, 2013Publication date: January 9, 2014Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventor: Pravin Kaumaya
-
Publication number: 20140010837Abstract: Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can comprise a nucleic acid sequence encoding an antigen fused to an immune cell product, e.g., MIP-3?, and an adjuvant. The antigen can be from a bacteria, virus, fungus, parasite, or cancer. The antigen can be an Alzheimer's disease antigen.Type: ApplicationFiled: September 11, 2013Publication date: January 9, 2014Applicant: Cyvax, Inc.Inventor: RICHARD MARKHAM
-
Patent number: 8623377Abstract: The present invention provides peptides that home to a joint of an animal, wherein said peptide comprises an amino acid motif selected from the group consisting of NQR and ADK. Also provided are methods of treating a subject having an arthritic joint, comprising the step of administering to said subject a pharmacologically effective dose of a composition provided herein.Type: GrantFiled: June 29, 2012Date of Patent: January 7, 2014Assignee: University of Maryland, BaltimoreInventors: Kamal Moudgil, Ying-hua Yang
-
Patent number: 8623348Abstract: Disclosed is an interferon-? (IFN-?) fused protein having IFN-? fused to a cytoplasmic transduction peptide (CTP). The disclosure relates to a fused protein wherein a CTP, which binds well to cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-?, thereby enhancing the conjugation capacity of cell membranes and antiviral activity, inhibiting CTP transport into the cell nucleus, and enhancing the translocation and settlement of the fused protein into the liver and of transduction to the liver tissue. Accordingly, it is possible to develop protein-based medicines effective for preventing or treating various liver diseases associated with viral infection at low doses.Type: GrantFiled: March 27, 2009Date of Patent: January 7, 2014Assignee: JW Pharmaceutical CorporationInventors: Chan Kyu Lee, Seonyoung Yang, Eun Ju Kang, Kang Ryu, Hyun Soo Lee, Yong Soo Bae
-
Publication number: 20140004181Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.Type: ApplicationFiled: September 6, 2013Publication date: January 2, 2014Applicant: Morehouse School of MedicineInventors: Vincent Craig BOND, Michael Powell, Ming Bo Huang, Syed Ali
-
Publication number: 20140004113Abstract: The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.Type: ApplicationFiled: September 9, 2013Publication date: January 2, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Larry W. Kwak, Bira Arya
-
Patent number: 8617566Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A beta-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.Type: GrantFiled: May 13, 2013Date of Patent: December 31, 2013Assignee: Novartis AGInventors: Ana Graf, Matthias Staufenbiel, Thomas Blaettler, Paolo Paganetti
-
Publication number: 20130344101Abstract: The present invention relates to the fields of immunology and molecular biology and related to a B7-1-PE40KDEL exotoxin fusion gene-based DNA vaccine and the use thereof. Specifically, the DNA vaccine contains a recombinant expression vector, and the vector contains exotoxin fusion gene B7-1-PE40KDEL, which is effectively ligated into selected eukaryotic expression vectors, such as pcDNA3.1/Zeo(+), pWLNEO, pSV2CAT, pOG44, pXT1, pSG, pSVK3, pBPV, pMSG, pSVL, and adenovirus. The invention also relates to the exotoxin fusion gene B7-1-PE40KDEL, the encoded exotoxin fusion protein, a recombinant expression vector that contains the exotoxin fusion gene, and compositions that contain the recombinant expression vector. The DNA vaccine in this invention has a good effect on the treatment or prevention of allogeneic tissue/organ transplant rejection and hematopoietic stem cell transplantation rejection such as GVHD.Type: ApplicationFiled: September 20, 2011Publication date: December 26, 2013Applicant: AFFILIATED HOSPITAL OF ACADEMY OF MILITARY MEDICAL SCIENCES, PLAInventors: Yongzhi Xi, Yuan Luo
-
Publication number: 20130344099Abstract: There is provided a fusion protein suitable for secretion of more than one polypeptide(s) of interest (POI) comprising a signal peptide, a POI, a passenger domain comprising a beta stem domain from an autotransporter protein, and a translocator domain from an autotransporter protein, wherein the beta stem-forming sequence of the passenger domain is essentially intact and the POI(s) is/are fused to the beta stem domain.Type: ApplicationFiled: September 28, 2011Publication date: December 26, 2013Applicant: ABERA BIOSCIENCE ABInventors: Joen Luirink, Wouter S. P. Jong
-
Publication number: 20130344100Abstract: A method of producing a virus like particle (VLP) in a plant, and compositions comprising VLPs, are provided. The method involves introducing a nucleic acid comprising a regulatory region active in the plant and operatively linked to a chimeric nucleotide sequence encoding, in series, an ectodomain from a virus trimeric surface protein or fragment thereof, fused to an influenza transmembrane domain and cytoplasmic tail, into the plant, or portion of the plant, the ectodomain is from a non-influenza virus trimeric surface protein and heterologous with respect to the influenza transmembrane domain, and the cytoplasmic tail. The plant or portion of the plant are incubated under conditions that permit the expression of the nucleic acid, thereby producing the VLP. A VLP produced by this method are also provided.Type: ApplicationFiled: December 22, 2011Publication date: December 26, 2013Applicant: MEDICAGO INC.Inventors: Marc-Andre D'Aoust, Manon Couture, Pierre-Olivier Lavoie, Louis-Philippe Vezina
-
Patent number: 8614183Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.Type: GrantFiled: November 12, 2010Date of Patent: December 24, 2013Assignee: Five Prime Therapeutics, Inc.Inventors: Thomas Harding, W. Michael Kavanaugh
-
Patent number: 8603473Abstract: The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.Type: GrantFiled: April 9, 2008Date of Patent: December 10, 2013Assignee: Biogen Idec MA Inc.Inventors: Scott Glaser, Mitchell Reff, Tzung-Horng Yang, Xiufeng Wu, Paul Chinn
-
Patent number: 8597658Abstract: This invention relates to fusion polypeptides comprised of a trimerization domain fused to a non-membrane bound, non-cleaved gp160 polypeptide derived from the R2 HIV-1 Env glycoprotein and to compositions comprising the fusion polypeptides. This invention further relates to oligomers of the fusion polypeptides. This invention also relates to nucleic acids encoding the fusion polypeptides. This invention also relates to diagnostic and therapeutic methods using the fusion polypeptides. Further, this invention relates to the induction of cross-reactive neutralizing antibodies against HIV-1, and to immunogenic compositions for the prevention and treatment of infection by HIV-1.Type: GrantFiled: November 12, 2008Date of Patent: December 3, 2013Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Gerald Quinnan, Christopher Broder
-
Patent number: 8597656Abstract: The present invention relates to a process for producing immunogenic polypeptides, comprising reducing disulfide bonds and blocking the resulting free thiol group with a blocking agent. The immunogenic peptides comprise a fragment of MAGE A3.Type: GrantFiled: December 13, 2011Date of Patent: December 3, 2013Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Teresa Cabezon Silva, Joseph Cohen, Moncef Mohamed Slaoui, Carlota Vinals Bassols
-
Patent number: 8597659Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-?2b.Type: GrantFiled: August 29, 2011Date of Patent: December 3, 2013Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Patent number: 8591890Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.Type: GrantFiled: September 30, 2011Date of Patent: November 26, 2013Inventors: Pramod K. Srivastava, Zihai Li
-
Patent number: 8592556Abstract: The invention encompasses phage ?mru including phage induction, phage particles, and the phage genome. Also encompassed are phage polypeptides, as well as polynucleotides which encode these polypeptides, expression vectors comprising these polynucleotides, and host cells comprising these vectors. The invention further encompasses compositions and methods for detecting, targeting, permeabilising, and inhibiting microbial cells, especially methanogen cells, using the disclosed phage, polypeptides, polynucleotides, expression vectors, or host cells.Type: GrantFiled: September 25, 2008Date of Patent: November 26, 2013Assignee: Pastoral Greenhouse Research LimitedInventors: Eric Heinz Altermann, Graeme Trevor Attwood, Sinead Christine Leahy, William John Kelly, Robert Starr Ronimus, Dong Li, Zhanhao Kong, Linley Rose Schofield, Debjit Dey, Catherine Mary Tootill, Carrie Sang, Christina Diane Moon, Petrus Hendricus Janssen
-
Publication number: 20130309265Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: ApplicationFiled: January 8, 2013Publication date: November 21, 2013Applicant: GLOBEIMMUNE, INC.Inventors: Richard Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
-
Patent number: 8586048Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: GrantFiled: June 11, 2012Date of Patent: November 19, 2013Assignees: Genexine, Inc., Postech Academy-Industry FoundationInventors: Sehwan Yang, Young Chul Sung
-
Patent number: 8586531Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: GrantFiled: June 11, 2012Date of Patent: November 19, 2013Assignees: Genexine, Inc., Postech Academy-Industry Foundation of Phohang University of Science and Technology (Postech)Inventors: Sehwan Yang, Young Chul Sung
-
Patent number: 8586038Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: GrantFiled: November 19, 2010Date of Patent: November 19, 2013Assignees: Genexine, Inc., Postech Academy-Industry Foundation of Phohang University of Science and Technology (Postech)Inventors: Sehwan Yang, Young Chul Sung
-
Patent number: 8586709Abstract: Signal peptides and polypeptides from Methanobrevibacter ruminantium, a methanogenic archaea present in ruminants. Methods of using these peptides to permeabilise microbial cells, particularly M. ruminantium strain M1? (DSM 1093).Type: GrantFiled: September 25, 2008Date of Patent: November 19, 2013Assignee: Pastoral Greenhouse Research LimitedInventors: Graeme Trevor Attwood, William John Kelly, Eric Heinz Altermann
-
Patent number: 8586052Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.Type: GrantFiled: April 24, 2012Date of Patent: November 19, 2013Assignee: Baylor Research InstituteInventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
-
Patent number: 8580273Abstract: The present invention refers to fusion proteins comprising a TNF superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a trimerization domain and a nucleic acid molecule encoding the fusion protein. The fusion protein is present as a trimeric complex or as an oligomer thereof and is suitable for therapeutic, diagnostic and/or research applications.Type: GrantFiled: February 23, 2012Date of Patent: November 12, 2013Assignee: Apogenix GmbHInventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
-
Patent number: 8580743Abstract: A recombinant galectin 9 (rGal 9) is provided which exhibits an immune system-mediated action and a direct action on tumor cells (i.e., activity of inducing the intercellular adhesion and apoptosis of the tumor cells), thereby potent in inducing the inhibition of cancer metastasis and reduction. Moreover, the rGal 9 exerts no efficacy on non-activated lymphocytes but can induce apoptosis in activated T cells, in particular, CD4-positive T cells causing an excessive immune response.Type: GrantFiled: August 22, 2012Date of Patent: November 12, 2013Assignee: Galpharma Co., Ltd.Inventors: Nozomu Nishi, Mitsuomi Hirashima, Akira Yamauchi, Aiko Ito
-
Patent number: 8580936Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: GrantFiled: September 7, 2011Date of Patent: November 12, 2013Assignee: Five Prime Therapeutics, Inc.Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
-
Publication number: 20130295128Abstract: The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally, the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune response against any kind of antigen. In one preferred aspect, the invention provides a method for treating a patient with cancer by providing a chimeric protein comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient.Type: ApplicationFiled: May 17, 2013Publication date: November 7, 2013Inventors: Thomas August, Ernesto Marques, JR.
-
Publication number: 20130287810Abstract: The present invention relates to vaccine compositions and uses thereof. Embodiments of the present invention provide oral bacterial (e.g., probiotic lactic acid bacteria) vaccine delivery systems comprising an antigen and a dendritic cell-targeting peptide. Such compositions target vaccines to dendritic cells, resulting in a high level of humoral and acquired immunity, including both mucosal and systemic immunity. Such delivery systems find use in the specific delivery of a wide variety of oral vaccines to subjects.Type: ApplicationFiled: January 18, 2013Publication date: October 31, 2013Applicant: NORTHWESTERN UNIVERSITYInventors: Mansour Mohamadzadeh, Todd R. Klaenhammer
-
Patent number: 8568989Abstract: The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Borrelia antigens. The peptide compositions comprise polypeptide sequences comprising variants in the IR6 domain of the Borrelia VlsE protein. The invention also provides devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Borrelia antigens and the diagnosis of Lyme disease.Type: GrantFiled: November 17, 2010Date of Patent: October 29, 2013Assignee: Abaxis, Inc.Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile
-
Patent number: 8568734Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.Type: GrantFiled: March 21, 2012Date of Patent: October 29, 2013Assignee: Novartis Vaccines and Diagnostics Inc.Inventors: Vega Masignani, Maria Scarselli, Barbara Capecchi, Victoria Sharma, Susan W Barnett, Indresh K. Srivastava, Rino Rappuoli
-
Patent number: 8568733Abstract: The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2/neu protein, including for uses in the treatment of malignancies associated with the HER-2/neu oncogene.Type: GrantFiled: April 9, 2008Date of Patent: October 29, 2013Assignee: GlaxoSmithKline Biologicals SAInventors: Martin A. Cheever, Dirk Gheysen
-
Patent number: 8563508Abstract: The invention describes peptide analogues of ?-melanocyte-stimulating hormone (?-MSH), which possess an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.Type: GrantFiled: March 19, 2013Date of Patent: October 22, 2013Assignee: AbbVie Inc.Inventors: Thomas E. N. Jonassen, Soren Nielsen, Jorgen Frokiaer, Bjarne Due Larsen
-
Patent number: 8563692Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).Type: GrantFiled: January 5, 2011Date of Patent: October 22, 2013Assignee: The Regents of the University of CaliforniaInventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
-
Patent number: 8563269Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: December 9, 2011Date of Patent: October 22, 2013Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Frederick W. Gluck, Jason Sagert, Patrick Daugherty
-
Patent number: 8563002Abstract: This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.Type: GrantFiled: December 23, 2008Date of Patent: October 22, 2013Assignee: GlaxoSmithKline Biologicals, S.A.Inventors: Guy Jean Marie Fernand Pierre Baudoux, Normand Blais, Patrick Rheault, Jean-Louis Ruelle
-
Patent number: 8557246Abstract: Fusion protein with directioning of vaccinal antigens toward antigen-presenting cells and the applications thereof. This invention relates to a gene construct that comprises, operatively bound, at least one nucleotide sequence (A) that encodes a polypeptide with SEQ ID NO: 1, which has a region that recognizes the ? chain of the class-II DR antigen present on the surface of antigen-presenting cells; and one nucleotide sequence (B) that encodes a vaccinal antigen of interest. Moreover, this invention relates to recombinant vectors useful for the expression of the gene construct of the invention, transgenic cells and plants transformed or transfected with said vectors, fusion proteins encoded by the gene construct of the invention and vaccines that comprise said fusion proteins.Type: GrantFiled: March 14, 2008Date of Patent: October 15, 2013Assignees: Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Alternative Gene Expression, S.L.Inventors: José Angel Martínez Escribano, Andrés Wigdorovitz, Félix Gil Dones, Agustin Ostachuk, Mariano Pèrez Filguera, Javier Dominguez, Carmen Núnez Serrano, Maria Josè Dus Santos, Covadonga Alonso Marti
-
Patent number: 8557243Abstract: Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described.Type: GrantFiled: July 14, 2011Date of Patent: October 15, 2013Assignee: The Scripps Research InstituteInventor: Carlos F. Barbas, III
-
Patent number: 8557248Abstract: Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can comprise a nucleic acid sequence encoding an antigen fused to an immune cell product, e.g., MIP-3?, and an adjuvant. The antigen can be from a bacteria, virus, fungus, parasite, or cancer. The antigen can be an Alzheimer's disease antigen.Type: GrantFiled: August 9, 2011Date of Patent: October 15, 2013Assignee: Cyvax, Inc.Inventor: Richard Markham
-
Patent number: 8557247Abstract: The present invention provides lyophilised compositions comprising an antigen and a Toll-like receptor (TLR) 9 agonist. Such compositions may be reconstituted into immunogenic compositions for use in vaccination with a carrier selected from the group of particulate carriers consisting of liposomes, mineral salts, emulsions, polymers and ISCOMs. Methods of making immunogenic compositions from the lyophilised compositions of the invention and use of the same in immunisation are also herein provided.Type: GrantFiled: November 15, 2010Date of Patent: October 15, 2013Assignee: GlaxoSmithKline Biologicals SAInventor: Dominique Ingrid Lemoine
-
Publication number: 20130266608Abstract: Compositions and methods for producing plant-derived immunogenic compositions that confer immunity against smallpox in a subject are provided. Plants engineered to produce antigenic proteins as well as expression cassettes comprising nucleic acids encoding proteins thereof are described. Methods of immunizing subjects with plant-derived compositions are also provided.Type: ApplicationFiled: March 22, 2013Publication date: October 10, 2013Applicant: PHARMA GREEN LLCInventor: Maxim Golovkin
-
Patent number: 8551480Abstract: The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to toxin alone, antibody alone, unconjugated toxin plus antibody or even other types of toxin-antibody constructs. In a most preferred embodiment the construct comprises an anti-Trop-2 antibody conjugated to Rap, although other combinations of antibodies, antibody fragments and toxins may be used to form the subject immunotoxins. The immunotoxins are of use to treat a variety of diseases, such as cancer, autoimmune disease or immune dysfunction.Type: GrantFiled: August 30, 2010Date of Patent: October 8, 2013Assignees: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Patent number: 8551495Abstract: The present invention pertains to the field of immunology and genetic engineering. In particular, the present invention relates to the construction, preparation and use of a recombinant vaccine against foot-and-mouth disease virus. The vaccine comprises a tandem repeat of an antigenic epitope of FMDV VP1 protein, the constant region of the immunoglobulin heavy chain or a functional fragment thereof, and the FMDV 3D protein or an immunogenic fragment thereof. The vaccine can induce protective immune response against FMDV in an animal.Type: GrantFiled: October 23, 2009Date of Patent: October 8, 2013Assignee: Pharos Vaccine Inc.Inventor: Yu Wang
-
Patent number: 8551494Abstract: This invention provides chimeric proteins comprising an apoptosis-inducing molecule fused to a member of a binding pair that is capable of binding to a selected cell that expresses a death receptor. When the selected cell is exposed in vivo or ex vivo to the chimeric protein, the selected cell undergoes apoptosis. The preferred embodiment is FasL protein fused to streptavidin. The methods of using the chimeric proteins are especially beneficial in causing activated lymphocytes to undergo apoptosis, thus modulating the immune response. Patients with conditions such as asthma or allergy, or patients undergoing transplantation with allogeneic or xenogeneic tissue are examples of patients who benefit from the methods of this invention.Type: GrantFiled: October 4, 2010Date of Patent: October 8, 2013Assignee: University of Louisville Research Foundation, Inc.Inventor: Haval Shirwan
-
Publication number: 20130259887Abstract: The present invention provides for modified reoviruses that carry ?-helical epitopes from a variety of pathogens, as well as methods of using such modified reoviruses to generate immune responses against those epitopes in hosts.Type: ApplicationFiled: April 4, 2011Publication date: October 3, 2013Inventors: Terence S. Dermody, Karl W. Boehme, Mine Ikizler, Gregory J. Wilson, James D. Chappell
-
Publication number: 20130259891Abstract: This invention relates to methods of using a Listeria vaccine vector to induce a Th1 immune response in subjects having persistent Th2 immune response profiles.Type: ApplicationFiled: October 3, 2011Publication date: October 3, 2013Inventors: Donald A. Harn, JR., Yvonne Paterson, Lisa Mcewen